Pathology of the Nervous System in Von Hippel-Lindau Disease

Main Article Content

Alexander O. Vortmeyer
Ahmed K. Alomari

Keywords

Endolymphatic sac tumors, Hemangioblastoma, Nervous system, Progenitor cells, VHL syndrome

Abstract

Von Hippel-Lindau (VHL) disease is a tumor syndrome that frequently involves the central nervous system (CNS). It is caused by germline mutation of the VHL gene. Subsequent VHL inactivation in selected cells is followed by numerous well-characterized molecular consequences, in particular, activation and stabilization of hypoxia-inducible factors HIF1 and HIF2. The link between VHL gene inactivation and tumorigenesis remains poorly understood. Hemangioblastomas are the most common manifestation in the CNS; however, CNS invasion by VHL disease-associated endolymphatic sac tumors or metastatic renal cancer also occur, and their differentiation from primary hemangioblastoma may be challenging. Finally, in this review, we present recent morphologic insights on the developmental concept of VHL tumorigenesis which is best explained by pathologic persistence of temporary embryonic progenitor cells.

Abstract 3878 | PDF Downloads 1194 HTML Downloads 6554

References

1. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2(9):673-82. http://dx.doi.org/10.1038/nrc885

2. Latif F et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317-20. http://dx.doi.org/10.1126/science.8493574

3. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059-67. http://dx.doi.org/10.1016/S0140-6736(03)13643-4

4. Haase VH. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin Cell Dev Biol. 2005;16(4-5):564-74. http://dx.doi.org/10.1016/j.semcdb.2005.03.006

5. Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, Grinberg A, Emmert-Buck MR, Westphal H, Klausner RD, Linehan WM. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A. 1997;94(17):9102-7. http://dx.doi.org/10.1073/pnas.94.17.9102

6. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell. 2003;3(1):75-88. http://dx.doi.org/10.1016/S1535-6108(02)00240-4

7. Nyhan MJ, O'Sullivan GC, McKenna SL. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans. 2008;36(Pt 3):472-8.
http://dx.doi.org/10.1042/BST0360472

8. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122(3):135-40. http://dx.doi.org/10.1007/BF01366952

9. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996;93(20):10595-9.
http://dx.doi.org/10.1073/pnas.93.20.10595

10. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19(48):5435-43. http://dx.doi.org/10.1038/sj.onc.1203938

11. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-5. http://dx.doi.org/10.1038/20459

12. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-32. http://dx.doi.org/10.1038/nrc1187

13. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997;11(1):72-82.
http://dx.doi.org/10.1101/gad.11.1.72

14. Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol. 2008;9(4):285-96. http://dx.doi.org/10.1038/nrm2354

15. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 1999;13(14):1822-33.
http://dx.doi.org/10.1101/gad.13.14.1822

16. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG Jr. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol. 1998;18(2):732-41.

17. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, Klausner RD. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A. 1997;94(6):2156-61. http://dx.doi.org/10.1073/pnas.94.6.2156

18. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000;275(33):25733-41. http://dx.doi.org/10.1074/jbc.M002740200

19. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2(7):423-7. http://dx.doi.org/10.1038/35017054

20. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem. 1997;272(31):19253-60. http://dx.doi.org/10.1074/jbc.272.31.19253

21. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A. 1997;94(9):4273-8. http://dx.doi.org/10.1073/pnas.94.9.4273

22. Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, Simon MC, Keith B, Haase VH. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117(4):1068-77.
http://dx.doi.org/10.1172/JCI30117

23. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A. 2007;104(7):2301-6.
http://dx.doi.org/10.1073/pnas.0608382104

24. Vortmeyer AO et al. Evolution of VHL tumourigenesis in nerve root tissue. J Pathol. 2006 Nov;210(3):374-82. http://dx.doi.org/10.1002/path.2062

25. Shively SB, Beltaifa S, Gehrs B, Duong H, Smith J, Edwards NA, Lonser R, Raffeld M, Vortmeyer AO. Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease. J Pathol. 2008;216(4):514-20. http://dx.doi.org/10.1002/path.2435

26. Lindau A. Studien uber Kleinhirncysten. Bau, Pathogenese und Beziehungen zur Angiomatosis retinae. Copenhagen; 1926.

27. Lindau A. Discussion on vascular tumors of the brain and spinal cord. Proc R Soc Med. 1931; 24: 363.

28. Vortmeyer AO, Falke EA, Glasker S, Li J, Oldfield EH. Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms. Acta Neuropathol. 2013;125(3):333-50.
http://dx.doi.org/10.1007/s00401-013-1091-z

29. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990;77(283):1151-63.
http://dx.doi.org/10.1093/qjmed/77.2.1151

30. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):82-94.
http://dx.doi.org/10.3171/jns.2003.98.1.0082

31. Grisoli F, Gambarelli D, Raybaud C, Guibout M, Leclercq T. Suprasellar hemangioblastoma. Surg Neurol. 1984;22(3):257-62. http://dx.doi.org/10.1016/0090-3019(84)90010-7

32. Neumann HP, Eggert HR, Weigel K, Friedburg H, Wiestler OD, Schollmeyer P. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg. 1989;70(1):24-30. http://dx.doi.org/10.3171/jns.1989.70.1.0024

33. Lonser RR, Vortmeyer AO, Butman JA, Glasker S, Finn MA, Ammerman JM, Merrill MJ, Edwards NA, Zhuang Z, Oldfield EH. Edema is a precursor to central nervous system peritumoral cyst formation. Ann Neurol. 2005;58(3):392-9. http://dx.doi.org/10.1002/ana.20584

34. Resche F, Moisan JP, Mantoura J, de Kersaint-Gilly A, Andre MJ, Perrin-Resche I, Menegalli-Boggelli D, Lajat Y, Richard S. Haemangioblastoma, haemangioblastomatosis, and von Hippel-Lindau disease. Adv Tech Stand Neurosurg. 1993;20:197-304. http://dx.doi.org/10.1007/978-3-7091-6912-4_6

35. Filling-Katz MR et al. Central nervous system involvement in Von Hippel-Lindau disease. Neurology. 1991;41(1):41-6. http://dx.doi.org/10.1212/WNL.41.1.41

36. Vortmeyer AO, Gnarra JR, Emmert-Buck MR, Katz D, Linehan WM, Oldfield EH, Zhuang Z. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol. 1997;28(5):540-3. http://dx.doi.org/10.1016/S0046-8177(97)90075-7

37. Lee JY et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res. 1998;58(3):504-8.

38. Plate K. H. VAO, Zagzag D., Neumann H.P.H. Familial Tumour Syndromes involving the Nervous System. In: Louis DN, ed. WHO classification of tumours of the central nervous system: World Health Organization (WHO), 2007.

39. Cushing H BP. Tumors Arising from the Blood-Vessels of the Brain. Angiomatous Malformations and Hemangioblastomas. In: Thomas CC, ed. Springfield, 1928.

40. Stein AA, Schilp AO, Whitfield RD. The histogenesis of hemangioblastoma of the brain. A review of twenty-one cases. J Neurosurg. 1960;17:751-61. http://dx.doi.org/10.3171/jns.1960.17.4.0751

41. Glasker S, Li J, Xia JB, Okamoto H, Zeng W, Lonser RR, Zhuang Z, Oldfield EH, Vortmeyer AO. Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res. 2006;66(8):4167-72. http://dx.doi.org/10.1158/0008-5472.CAN-05-3505

42. Vortmeyer AO et al. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res. 2003;63(21):7051-5.

43. Sabin FR. Preliminary note on the differentiation of angioblasts and the method by which they produce blood-vessels, blood-plasma and red blood-cells as seen in the living chick. 1917. J Hematother Stem Cell Res. 2002;11(1):5-7. http://dx.doi.org/10.1089/152581602753448496

44. Sabin FR. Studies on the origin of the blood vessels and of red blood corpuscles as seen in the living blastoderm of chick during the second day of incubation. Carnegie Contrib Embryol. 1920; 9: 215.

45. Sabin FR. Preliminary note on the differentiation of angioblasts and the method by which they produce blood-vessels, blood-plasma and red blood-cells as seen in the living chick. Anat Rec. 1917; 13: 199.
http://dx.doi.org/10.1002/ar.1090130403

46. Glasker S, Smith J, Raffeld M, Li J, Oldfield EH, Vortmeyer AO. VHL-deficient vasculogenesis in hemangioblastoma. Exp Mol Pathol. 2014;96(2):162-7. http://dx.doi.org/10.1016/j.yexmp.2013.12.011

47. Wizigmann-Voos S, Breier G, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 1995;55(6):1358-64.

48. Tanimura A, Nakamura Y, Hachisuka H, Tanimura Y, Fukumura A. Hemangioblastoma of the central nervous system: nature of the stromal cells as studied by the immunoperoxidase technique. Hum Pathol. 1984;15(9):866-9. http://dx.doi.org/10.1016/S0046-8177(84)80148-3

49. Becker I, Paulus W, Roggendorf W. Histogenesis of stromal cells in cerebellar hemangioblastomas. An immunohistochemical study. Am J Pathol. 1989;134(2):271-5.

50. Frank TS, Trojanowski JQ, Roberts SA, Brooks JJ. A detailed immunohistochemical analysis of cerebellar hemangioblastoma: an undifferentiated mesenchymal tumor. Mod Pathol. 1989;2(6):638-51.

51. Nemes Z. Fibrohistiocytic differentiation in capillary hemangioblastoma. Hum Pathol. 1992;23(7):805-10. http://dx.doi.org/10.1016/0046-8177(92)90351-3

52. Kamitani H, Masuzawa H, Sato J, Kanazawa I. Capillary hemangioblastoma: histogenesis of stromal cells. Acta Neuropathol. 1987;73(4):370-8. http://dx.doi.org/10.1007/BF00688262

53. Cruz-Sanchez FF, Rossi ML, Rodriguez-Prados S, Nakamura N, Hughes JT, Coakham HB. Haemangioblastoma: histological and immunohistological study of an enigmatic cerebellar tumour. Histol Histopathol. 1990;5(4):407-13.
54. Jurco S 3rd, Nadji M, Harvey DG, Parker JC Jr, Font RL, Morales AR. Hemangioblastomas: histogenesis of the stromal cell studied by immunocytochemistry. Hum Pathol. 1982;13(1):13-8.
http://dx.doi.org/10.1016/S0046-8177(82)80133-0

55. Omulecka A, Lach B, Alwasiak J, Gregor A. Immunohistochemical and ultrastructural studies of stromal cells in hemangioblastoma. Folia Neuropathol. 1995;33(1):41-50.

56. Lach B, Gregor A, Rippstein P, Omulecka A. Angiogenic histogenesis of stromal cells in hemangioblastoma: ultrastructural and immunohistochemical study. Ultrastruct Pathol. 1999;23(5):299-310. http://dx.doi.org/10.1080/019131299281446

57. Spence AM, Rubinstein LJ. Cerebellar capillary hemangioblastoma: its histogenesis studied by organ culture and electron microscopy. Cancer. 1975;35(2):326-41. http://dx.doi.org/10.1002/1097-0142(197502)35:2<326::AID-CNCR2820350206>3.0.CO;2-8

58. Park DM et al. von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med. 2007;4(2):e60. http://dx.doi.org/10.1371/journal.pmed.0040060

59. Zhuang Z, Frerich JM, Huntoon K, Yang C, Merrill MJ, Abdullaev Z, Pack SD, Shively SB, Stamp G, Lonser RR. Tumor derived vasculogenesis in von Hippel-Lindau disease-associated tumors. Sci Rep. 2014;4:4102. http://dx.doi.org/10.1038/srep04102

60. Hasselblatt M, Jeibmann A, Gerss J, Behrens C, Rama B, Wassmann H, Paulus W. Cellular and reticular variants of haemangioblastoma revisited: a clinicopathologic study of 88 cases. Neuropathol Appl Neurobiol. 2005;31(6):618-22. http://dx.doi.org/10.1111/j.1365-2990.2005.00669.x

61. Netter FH CS. Atlas of Human Anatomy. Summit: Ciba Geigy Corporation, 1989. PMCid:PMC1003780

62. Lo WW, Daniels DL, Chakeres DW, Linthicum FH Jr, Ulmer JL, Mark LP, Swartz JD. The endolymphatic duct and sac. AJNR Am J Neuroradiol. 1997;18(5):881-7.

63. Arenberg IK, Rask-Andersen H, Wilbrand H, Stahle J. The surgical anatomy of the endolymphatic sac. Arch Otolaryngol. 1977;103(1):1-11. http://dx.doi.org/10.1001/archotol.1977.00780180039001

64. Glasker S, Lonser RR, Tran MG, Ikejiri B, Butman JA, Zeng W, Maxwell PH, Zhuang Z, Oldfield EH, Vortmeyer AO. Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res. 2005;65(23):10847-53.
http://dx.doi.org/10.1158/0008-5472.CAN-05-1104

65. Wackym PA1, Glasscock ME 3rd, Linthicum FH Jr, Friberg U, Rask-Andersen H. Immunohistochemical localization of Na+, K+-ATPase in the human endolymphatic sac. Arch Otorhinolaryngol. 1988;245(4):221-3. http://dx.doi.org/10.1007/BF00463931

66. Morgenstern C, Amano H, Orsulakova A. Ion transport in the endolymphatic space. Am J Otolaryngol. 1982;3(5):323-7. http://dx.doi.org/10.1016/S0196-0709(82)80004-5

67. Erwall C, Friberg U, Bagger-Sjoback D, Rask-Andersen H. Degradation of the homogeneous substance in the endolymphatic sac. Acta Otolaryngol. 1988;105(3-4):209-17. http://dx.doi.org/10.3109/00016488809097000

68. Harris JP. Autoimmunity of the inner ear. Am J Otol. 1989;10(3):193-5.

69. Heffner DK. Low-grade adenocarcinoma of probable endolymphatic sac origin A clinicopathologic study of 20 cases. Cancer. 1989;64(11):2292-302. http://dx.doi.org/10.1002/1097-0142(19891201)64:11<2292::AID-CNCR2820641119>3.0.CO;2-#

70. Manski TJ et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA. 1997;277(18):1461-6. http://dx.doi.org/10.1001/jama.1997.03540420057030

71. Kawahara N, Kume H, Ueki K, Mishima K, Sasaki T, Kirino T. VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease. Neurology. 1999;53(1):208-10. http://dx.doi.org/10.1212/WNL.53.1.208

72. Vortmeyer AO, Choo D, Pack SD, Oldfield E, Zhuang Z. von Hippel-Lindau disease gene alterations associated with endolymphatic sac tumor. J Natl Cancer Inst. 1997;89(13):970-2. http://dx.doi.org/10.1093/jnci/89.13.970-a

73. Vogel TW, Vortmeyer AO, Lubensky IA, Lee YS, Furuta M, Ikejiri B, Kim HJ, Lonser RR, Oldfield EH, Zhuang Z. Coexpression of erythropoietin and its receptor in endolymphatic sac tumors. J Neurosurg. 2005;103(2):284-8. http://dx.doi.org/10.3171/jns.2005.103.2.0284

74. Megerian CA, Haynes DS, Poe DS, Choo DI, Keriakas TJ, Glasscock ME 3rd. Hearing preservation surgery for small endolymphatic sac tumors in patients with von Hippel-Lindau syndrome. Otol Neurotol. 2002;23(3):378-87. http://dx.doi.org/10.1097/00129492-200205000-00026

75. Thompson LD. Endolymphatic sac tumor. Ear Nose Throat J. 2013;92(4-5):184-8.

76. Butman JA, Kim HJ, Baggenstos M, Ammerman JM, Dambrosia J, Patsalides A, Patronas NJ, Oldfield EH, Lonser RR. Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA. 2007;298(1):41-8. http://dx.doi.org/10.1001/jama.298.1.41

77. Lonser RR, Kim HJ, Butman JA, Vortmeyer AO, Choo DI, Oldfield EH. Tumors of the endolymphatic sac in von Hippel-Lindau disease. N Engl J Med. 2004;350(24):2481-6. http://dx.doi.org/10.1056/NEJMoa040666

78. Du J, Wang JM, Cui Y, Li GL. [Clinicopathologic features of endolymphatic sac tumor at cerebellopontine angle]. Zhonghua Bing Li Xue Za Zhi. 2011;40(9):590-4 (Chinese journal of pathology. 2011; 40(9): 590-4).

79. Kempermann G, Neumann HP, Volk B. Endolymphatic sac tumours. Histopathology. 1998;33(1):2-10. http://dx.doi.org/10.1046/j.1365-2559.1998.00460.x

80. Michaels L. Origin of endolymphatic sac tumor. Head Neck Pathol. 2007;1(2):104-11. http://dx.doi.org/10.1007/s12105-007-0016-3

81. Andrew SM, Gradwell E. Immunoperoxidase labelled antibody staining in differential diagnosis of central nervous system haemangioblastomas and central nervous system metastases of renal carcinomas. J Clin Pathol. 1986;39(8):917-9. http://dx.doi.org/10.1136/jcp.39.8.917

82. Gouldesbrough DR, Bell JE, Gordon A. Use of immunohistochemical methods in the differential diagnosis between primary cerebellar haemangioblastoma and metastatic renal carcinoma. J Clin Pathol. 1988;41(8):861-5. http://dx.doi.org/10.1136/jcp.41.8.861

83. Vortmeyer AO, Weil RJ, Zhuang Z. Proteomic applications for differential diagnosis of histologically identical tumors. Neurology. 2003;61(11):1626-7. http://dx.doi.org/10.1212/01.WNL.0000096168.85260.60

84. Hoang MP, Amirkhan RH. Inhibin alpha distinguishes hemangioblastoma from clear cell renal cell carcinoma. Am J Surg Pathol. 2003;27(8):1152-6. http://dx.doi.org/10.1097/00000478-200308000-00014

85. Ingold B, Wild PJ, Nocito A, Amin MB, Storz M, Heppner FL, Moch H. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. Histopathology. 2008;52(6):674-81. http://dx.doi.org/10.1111/j.1365-2559.2008.03003.x

86. Jung SM, Kuo TT. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol. 2005;18(6):788-94.
http://dx.doi.org/10.1038/modpathol.3800351

87. Roy S, Chu A, Trojanowski JQ, Zhang PJ. D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathol. 2005;109(5):497-502. http://dx.doi.org/10.1007/s00401-005-0999-3

88. Weinbreck N, Marie B, Bressenot A, Montagne K, Joud A, Baumann C, Klein O, Vignaud JM. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining. Am J Surg Pathol. 2008;32(7):1051-9. http://dx.doi.org/10.1097/PAS.0b013e3181609d7d

89. Carney EM, Banerjee P, Ellis CL, Albadine R, Sharma R, Chaux AM, Burger PC, Netto GJ. PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. Am J Surg Pathol. 2011;35(2):262-7. http://dx.doi.org/10.1097/PAS.0b013e3182064d11

90. Jarrell ST, Vortmeyer AO, Linehan WM, Oldfield EH, Lonser RR. Metastases to hemangioblastomas in von Hippel-Lindau disease. J Neurosurg. 2006;105(2):256-63. http://dx.doi.org/10.3171/jns.2006.105.2.256

91. Mottolese C, Stan H, Giordano F, Frappaz D, Alexei D, Streichenberger N. Metastasis of clear-cell renal carcinoma to cerebellar hemangioblastoma in von Hippel Lindau disease: rare or not investigated? Acta Neurochir (Wien). 2001;143(10):1059-63. http://dx.doi.org/10.1007/s007010170012

92. Sell S. Stem Cells and Cancer. New York: Springer, 2009.

93. Grundmann E. [The concept of Julius Cohnheim on tumor formation and metastasis from the viewpoint of new research results]. Zentralbl Allg Pathol. 1985;130(4):323-31.

94. Durante F. Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memor Osser Chir Pract 1874;11:217–226.

95. Bainbridge W. The cancer problem. New York: The Macmillan Company, 1918.

96. Sell S. On the stem cell origin of cancer. Am J Pathol. 2010;176(6):2584-494. http://dx.doi.org/10.2353/ajpath.2010.091064

97. Shively SB, Falke EA, Li J, Tran MG, Thompson ER, Maxwell PH, Roessler E, Oldfield EH, Lonser RR, Vortmeyer AO.. Developmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau disease. Mod Pathol. 2011;24(8):1023-30. http://dx.doi.org/10.1038/modpathol.2011.61

98. Vortmeyer AO, Yuan Q, Lee YS, Zhuang Z, Oldfield EH. Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol. 2004;55(5):721-8. http://dx.doi.org/10.1002/ana.20090

99. Glasker S, Sohn TS, Okamoto H, Li J, Lonser RR, Oldfield EH, Vortmeyer AO, Zhuang Z. Second hit deletion size in von Hippel-Lindau disease. Ann Neurol. 2006;59(1):105-10. http://dx.doi.org/10.1002/ana.20704

100. Visvader JE. Cells of origin in cancer. Nature. 2011;469(7330):314-22. http://dx.doi.org/10.1038/nature09781

101. Liu C, Chen Z, Chen Z, Zhang T, Lu Y. Multiple tumor types may originate from bone marrow-derived cells. Neoplasia. 2006;8(9):716-24. http://dx.doi.org/10.1593/neo.06253

102. Ratajczak MZ, Sellers ZP, Kucia M, Kakar SS. The embryonic rest hypothesis of cancer development - and old XIX century theory revisited. J Cancer Stem Cell Res 01/2014; 1(1):1. DOI: 10.14343/JCSCR.2014.1e1001

103. White AC, Lowry WE. Refining the role for adult stem cells as cancer cells of origin. Trends Cell Biol. 2015;25(1):11-20. http://dx.doi.org/10.1016/j.tcb.2014.08.008